RecruitingPhase 3NCT07246187
Comparing Haloperidol to Olanzapine in the Treatment of Suspected Cannabinoid Hyperemesis in the Emergency Department
Sponsor
Mercy Bon Secours Saint Vincent Medical Center
Enrollment
114 participants
Start Date
Nov 6, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
The aim of the study is to identify which medication (haloperidol or olanzapine) is most effective in treating nausea and abdominal pain associated with cannabinoid hyperemesis using a 10-point visual analog scale with intervals of 0.5.
Eligibility
Min Age: 18 YearsMax Age: 100 Years
Inclusion Criteria4
- subjects must meet ONE of the below criteria AND are a near-daily to daily user of cannabis by inhalation for greater than or equal to 6 months.
- Have documented previous diagnosis of cannabinoid hyperemesis, or
- Report (or on chart review) greater than or equal to 3 episodes of emesis in a cyclic pattern separated by greater than 1 month during the preceding 2 years, or
- The provider suspects cannabinoid hyperemesis as the primary or equally likely primary diagnosis.
Exclusion Criteria1
- Ineligible subjects include age less than 18 years, weight less than 50 kg, pregnancy, daily benzodiazepines use, prolonged QTc interval on the electrocardiogram (ECG), breastfeeding mothers, previously known allergy to or intolerance of either study drug, subjects taking drugs that are contraindicated with haloperidol or olanzapine, subjects with Parkison's Disease, subjects already taking haloperidol, olanzapine, or other antipsychotics
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGOlanzapine 10 milligram
olanzapine 10 mg IM
DRUGHaloperidol
Haloperidol 5 mg IM
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07246187